
|Articles|July 1, 2006
Immune response modifier post-op
San Francisco - Results from several studies performed with imiquimod 5 percent cream (Aldara, 3M Pharmaceuticals) suggest that the immune response modifier may have a role as a surgical adjuvant for improving local tumor control and/or to enhance scar appearance, says James M. Spencer, M.D., M.S., clinical professor of dermatology, Mt. Sinai School of Medicine, New York.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
3
ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN
4
Dermatology Conferences and Meetings Calendar: December 2025
5


















